Cadrenal Therapeutics Inc
Cadrenal Therapeutics Inc Stock, NASDAQ:CVKD
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham on January 25, 2022 and is headquartered in Ponte Vedra, FL.